HIGHLIGHTS
- who: Junjie Lu from the Nanjing Medical University, China have published the Article: Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials, in the Journal: (JOURNAL)
- what: Clinical trials in NSCLC have shown that bone metastasis is very common in nonsmall cell lung cancer; one clinical trial confirmed that 50%-60% of NSCLC tumor tissues express RANKL and RANK, and the trial showed that denosumab can directly block RANKL to inhibit bone metastasis in NSCLC.
- future: Since the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.